Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IBO

Impact BioMedical Inc

Dec 04 • 04:00PM ET

2.39

Dollar change +0.09
Percentage change 3.91	%

Healthcare • Biotechnology • USA • AMEX

Peers: VRTX GILD REGN BIIB ALNY BMRN NBIX INCY IONS SRPT

Scroll to Statements

Index	-	P/E	26.76	EPS (ttm)	0.09	Insider Own	55.63%	Shs Outstand	11.50M	Perf Week	-12.45%
Market Cap	27.49M	Forward P/E	-	EPS next Y	-	Insider Trans	0.86%	Shs Float	5.10M	Perf Month	-12.13%
Income	1.16M	PEG	-	EPS next Q	-	Inst Own	0.57%	Short Float	0.10%	Perf Quarter	-
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	0.99%	Short Ratio	0.06	Perf Half Y	-
Book/sh	2.72	P/B	0.88	EPS next Y	-	ROA	2.53%	Short Interest	0.01M	Perf Year	-
Cash/sh	0.23	P/C	10.29	EPS next 5Y	-	ROE	4.01%	52W Range	1.22 - 3.25	Perf YTD	-10.82%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	2.95%	52W High	-26.46%	Beta	-
Dividend TTM	-	Quick Ratio	2.79	Sales past 5Y	0.00%	Gross Margin	-	52W Low	95.90%	ATR (14)	0.46
Dividend Ex-Date	-	Current Ratio	2.79	EPS Y/Y TTM	115.92%	Oper. Margin	-	RSI (14)	46.67	Volatility	18.93% 20.35%
Employees	-	Debt/Eq	0.26	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.25	EPS Q/Q	465.54%	Payout	-	Rel Volume	0.25	Prev Close	2.30
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	91.77K	Price	2.39
SMA20	-11.17%	SMA50	10.08%	SMA200	8.21%	Trades		Volume	22,634	Change	3.91%

Nov-19-24 08:00AM	Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision (GlobeNewswire) -17.44%
Nov-18-24 07:00AM	Impact BioMedical Inc. (NYSEAmerican: IBO): Targeting Chronic Diseases with Patented Breakthroughs (News Direct)
Nov-11-24 07:30AM	Positioned for Growth: Impact BioMedical Inc.'s (NYSEAmerican: IBO) Push into Cancer and Immune Health (News Direct) -9.31%
Oct-15-24 06:00AM	Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker Technology Targeting Inflammatory Disease (GlobeNewswire) +19.20%
Oct-07-24 08:30AM	Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates (GlobeNewswire) +5.50%
08:30AM	Loading…
Sep-26-24 08:30AM	Impact BioMedical Inc. (NYSE: IBO) Announces 3F US Patent Issue (GlobeNewswire)
Sep-23-24 08:00AM	Impact BioMedical Inc. Introduces Leadership Team to Drive Innovation and Growth (GlobeNewswire) +6.87%
Sep-17-24 11:29AM	Impact BioMedical Inc. Announces the Closing of its Initial Public Offering (GlobeNewswire) -13.06%
Sep-16-24 04:26PM	DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value (GlobeNewswire)
10:24AM	Impact BioMedical Inc. Announces Pricing of Initial Public Offering (GlobeNewswire)

Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The firm focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. It is also involved in developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. The company was founded on October 16, 2018 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heuszel Frank D	Chief Executive Officer	Nov 27 '24	Buy	2.61	500	1,305	96,844	Dec 03 09:51 PM
Heuszel Frank D	Chief Executive Officer	Nov 26 '24	Buy	2.61	1,050	2,739	96,344	Dec 03 09:49 PM
DSS, INC.	10% Owner	Nov 18 '24	Sale	3.02	5,000	15,085	53,100	Nov 22 04:33 PM
DSS, INC.	10% Owner	Nov 12 '24	Sale	2.76	500	1,378	58,300	Nov 22 04:33 PM
DSS, INC.	10% Owner	Nov 13 '24	Sale	2.80	200	560	58,100	Nov 22 04:33 PM
DSS, INC.	10% Owner	Sep 18 '24	Buy	2.33	1,000	2,330	58,800	Sep 19 07:07 PM
DSS, INC.	10% Owner	Sep 16 '24	Buy	2.69	50,000	134,500	50,000	Sep 18 08:53 PM
DSS, INC.	10% Owner	Sep 17 '24	Buy	2.40	7,800	18,720	57,800	Sep 18 08:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IBO

Impact BioMedical Inc

Upgrade your FINVIZ experience